Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Tango Therapeutics (TNGX) over the last 6 years, with Q2 2025 value amounting to $110.5 million.

  • Tango Therapeutics' Shares Outstanding (Weighted Average) rose 170.02% to $110.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $110.5 million, marking a year-over-year increase of 170.02%. This contributed to the annual value of $109.2 million for FY2024, which is 1549.53% up from last year.
  • According to the latest figures from Q2 2025, Tango Therapeutics' Shares Outstanding (Weighted Average) is $110.5 million, which was up 170.02% from $110.3 million recorded in Q1 2025.
  • In the past 5 years, Tango Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $110.5 million in Q2 2025 and a low of $41.6 million during Q1 2021
  • For the 5-year period, Tango Therapeutics' Shares Outstanding (Weighted Average) averaged around $88.8 million, with its median value being $88.3 million (2023).
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 11087.28% in 2022, then surged by 58.61% in 2023.
  • Tango Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $62.1 million in 2021, then surged by 41.4% to $87.8 million in 2022, then rose by 7.69% to $94.6 million in 2023, then rose by 15.5% to $109.2 million in 2024, then rose by 1.2% to $110.5 million in 2025.
  • Its last three reported values are $110.5 million in Q2 2025, $110.3 million for Q1 2025, and $109.2 million during Q4 2024.